1Fuster V,Ryden LE,Asinger RW,et al .ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation:Executive summary.A Report of the American College of Cardiology/American Heart Association Task Force on Pratice Guidelines and the Europea
2Yamaguchi T.Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation:A multicenter,prospective,randomized trial[J].Stroke,2000;31(4):817-821.
2Hirsh J, Fuster V,Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. JAm Coll Cardiol,2003,41 (9):1633-1652
3The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillationand recent cerebral ischemia. N Engl J Med,1995,333(1) :5-10
4Yamaguchi T. Optimal intensity of warfarin therapy for secondaryprevention of stroke in patients with nonvalvular atrial fibrillation. Amulticenter, prospective, randomized trial. Stroke, 2000,31 (4): 817 -821
6Beyth RJ, Quirm L, Landefeld CS. A multieompenent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med, 2000,133 (9) : 687-695.
7Gedge J,Orme S,Hampton KK,et al. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing, 2000,29 ( 1 ) : 31-34.
8Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen. Blood, 2005,106(7 ) :2329-2333.
9Kamli F,Khan TI,King BP,et al. Contribution of age,body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther, 2004,75 (3) : 204-212.
10Self TH, Reaves AB, Oliphant CS, et al. Does heart failure exacerbation increase response to warfarin? A critical review of the literature. Curr Med Res Opin,2006,22( 11 ) : 2089-2094.
